Prime Medicine, Inc.
PRME
$3.67
$0.020.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 838.00K | 1.23M | 1.12M | 1.45M | 2.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 838.00K | 1.23M | 1.12M | 1.45M | 2.18M |
| Cost of Revenue | 34.71M | 43.99M | 3.22M | 2.86M | 34.10M |
| Gross Profit | -33.87M | -42.77M | -2.10M | -1.40M | -31.92M |
| SG&A Expenses | 14.74M | 11.21M | 13.12M | 13.28M | 12.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.45M | 55.20M | 54.49M | 53.85M | 46.41M |
| Operating Income | -48.61M | -53.97M | -53.38M | -52.39M | -44.22M |
| Income Before Tax | -46.08M | -50.58M | -52.59M | -51.89M | -42.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.08M | -50.58M | -52.59M | -51.89M | -42.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.08M | -50.58M | -52.59M | -51.89M | -42.28M |
| EBIT | -48.61M | -53.97M | -53.38M | -52.39M | -44.22M |
| EBITDA | -46.73M | -52.09M | -51.51M | -50.69M | -42.51M |
| EPS Basic | -0.26 | -0.32 | -0.41 | -0.40 | -0.32 |
| Normalized Basic EPS | -0.17 | -0.21 | -0.25 | -0.24 | -0.20 |
| EPS Diluted | -0.26 | -0.32 | -0.41 | -0.40 | -0.32 |
| Normalized Diluted EPS | -0.17 | -0.21 | -0.25 | -0.24 | -0.20 |
| Average Basic Shares Outstanding | 177.30M | 160.50M | 129.19M | 130.88M | 130.92M |
| Average Diluted Shares Outstanding | 177.30M | 160.50M | 129.19M | 130.88M | 130.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |